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Leading Edge
EssayFive years ago, Tuschl and colleagues 
showed that RNA interference (RNAi) 
works in mammalian cells. They 
found that the endogenous RNAi 
pathway can be harnessed by intro-
ducing small double-stranded RNAs 
comprising 19–21 nucleotide com-
plementary sequences (called 
small interfering RNAs, siR-
NAs) into mammalian cells 
to silence gene expression 
with exquisite specificity and 
without activating an inter-
feron response (Elbashir et al., 
2001). Translational research-
ers were quick to realize the 
potential for using RNAi to 
identify new drug targets and 
for designing small molecule 
drugs. siRNA-based drug 
development has proceeded 
at a dizzying pace. The first 
demonstration of disease 
protection using siRNAs in a 
mouse model was published 
three years ago (Song et al., 
2003b), and human safety 
clinical studies began a little 
over a year later, well before 
much of the basic phenomena 
of RNAi were really under-
stood. Some believe, and we 
agree, that siRNAs have the 
potential to become the next 
new class of drugs. Three 
phase I clinical studies investi-
gating siRNAs for treating age-
related macular degeneration 
and respiratory syncytial virus 
(RSV) infection have been 
completed with no reports of 
untoward toxicity. The abil-
ity to design siRNAs to any 
host gene or pathogen once genetic 
sequences are known and test them 
rapidly highlights a key advantage of 
siRNA drug development compared 
to more conventional small molecule 
drugs. For example, the human phase 
I study of siRNAs targeting RSV by 
Alnylam began just 15 months after 
the company starting working on this 
project (A. de Fougerolles, personal 
 communication).
In the original RNAi studies, gene 
expression was silenced by trans-
ducing cultured mammalian cell lines 
with siRNAs or with viral vec-
tors encoding short hairpin 
RNAs (shRNAs) processed 
within cells like endogenous 
microRNAs. These two 
approaches—siRNA small 
molecule drugs or shRNA 
gene therapy—are the two 
pathways available for har-
nessing RNAi in both research 
and the development of ther-
apeutics. The gene therapy 
application of RNAi is likely to 
remain mostly an academic 
exercise for the immediate 
future. Early clinical studies 
have focused on using siR-
NAs as small molecule drugs. 
However, as we discuss in this 
Essay, there are many hurdles 
to be overcome before siRNA 
drugs become a reality.
Delivery
To be useful as drugs, siR-
NAs need to be delivered in 
vivo into the cytoplasm of 
cells. Here, the RNA-induced 
silencing complexes (RISC) 
take up the double-stranded 
siRNAs and cleave the sense 
passenger strand, leaving the 
activated RISC containing the 
antisense strand to search for 
mRNAs containing comple-
mentary sequences, which 
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Knocking down expression of disease-related genes using small interfering RNAs (siRNAs) 
has potential for treating a variety of illnesses. This Essay will examine the opportunities 
for harnessing RNA interference (RNAi) for therapy, as well as the obstacles and possible 
ways to circumvent them.
Figure 1. The Cellular Pathway for siRNA Drug Action
Small interfering RNAs introduced into the cytoplasm are 
taken up by the RISC. The strand whose 5′-end is less tightly 
bound is incorporated as the active guide strand, whereas 
the other strand (the passenger strand) is cleaved. This acti-
vates the RISC, which then recognizes a target mRNA bearing 
a complementary sequence and cleaves it. Once the target 
mRNA is cleaved the RISC can be recycled to seek and de-
stroy another mRNA. The potency of siRNA drugs is linked to 
their incorporation and stabilization in the endogenous RISC 
complex present in all cells, and the catalytic nature of the 
cleavage reaction.Cell 126, July 28, 2006 ©2006 Elsevier Inc. 231
will then be targeted for degradation 
(Figure 1). Although siRNAs are read-
ily taken up by invertebrate cells, siR-
NAs on their own are not taken up by 
most mammalian cells in a way that 
preserves their activity. Even cells 
that are actively sampling their envi-
ronment, such as dendritic cells and 
macrophages, do not take up siRNAs 
efficiently enough to activate gene 
silencing. Although lipid-based trans-
fection can introduce siRNAs into a 
variety of cells in vitro, many important 
cells, such as primary lymphocytes or 
hematopoietic stem cells, are refrac-
tory to transfection (although nucleo-232 Cell 126, July 28, 2006 ©2006 ElsevieSome tissues of the body that 
are easily accessible, including the 
respiratory and genital tracts and 
the eye, can take up siRNAs after 
topical application or direct injec-
tion of naked siRNAs alone or in 
complexes with cationic lipids used 
for in vitro transfection (Bitko et al., 
2005; Palliser et al., 2006). Phase I 
clinical studies to treat age-related 
macular degeneration of the retina 
and RSV in the respiratory tract 
have demonstrated uptake in those 
target tissues after intravitreal injec-
tion and intranasal application of 
naked siRNAs, respectively. Cells Figure 2. Delivery of siRNAs for Therapy
To be a useful drug, an siRNA (top) must be delivered into cells in vivo. Methods to accomplish 
this (middle) include chemical conjugation of the passenger strand to cholesterol; binding of the 
siRNA to an antibody fragment-protamine fusion protein for cell receptor-mediated uptake; in-
corporation of the siRNA into specialized liposomes or nanoparticles; or expression of an shRNA 
precursor from a viral vector. (Bottom) Delivered siRNAs can then be tested in small animals, 
nonhuman primates, and people. Application of siRNAs to mucosal tissues such as the lungs 
(using an inhaler, for example) does not require specialized delivery methods.fection, a proprietary electroporation 
method developed by Amaxa, does 
work for these cells). Moreover, these 
methods of intracellular delivery are 
not suitable for in vivo use. There-
fore, siRNA intracellular delivery has 
been the most formidable obstacle to 
siRNA drug development. Practical 
solutions to the delivery problem are, 
however, becoming available.in the epithelium and lamina pro-
pria of the mouse vagina and cervix 
very efficiently take up siRNA-lipid 
complexes. It may well be that most 
cells at the mucosal surfaces of 
the body efficiently internalize siR-
NAs, suggesting that topical siRNA 
therapies have the fewest hurdles 
to overcome. Given that mucosal 
surfaces are the portals of entry for r Inc.most pathogens, the use of topically 
applied siRNAs to prevent or treat 
intracellular infection is an attrac-
tive option, especially for viral infec-
tions for which few drugs exist. For 
example, local siRNA delivery to the 
lung was able to protect nonhuman 
primates from infection with the 
SARS coronavirus (Li et al., 2005). 
Other opportunities for local treat-
ment include localized inflammatory 
diseases such as seasonal rhini-
tis or mucosal malignancies such 
as cancers of the head and neck, 
nasopharynx, or cervix (some of 
which are caused by transforming 
viruses, providing specific gene tar-
gets). Targeting inflammatory lung 
diseases, such as asthma, is also 
high on the agenda of at least one 
RNAi biotechnology company. This 
will require aerosolized delivery to 
introduce siRNAs into the appropri-
ate epithelial and immune cells deep 
within the lung. However, it is still 
not clear which primary cell types 
in accessible tissues efficiently take 
up naked siRNAs or siRNA-lipid 
complexes and would be amenable 
to local siRNA therapeutic deliv-
ery. Moreover, the mechanism of 
uptake into mammalian cells is not 
understood. Answering these ques-
tions will be important for choosing 
the best disease targets for RNAi 
 therapeutics.
The earliest studies showing siRNA 
effectiveness systemically in animal 
disease models relied on hydrody-
namic injection. With this technique, 
siRNAs are injected rapidly in a large 
bolus that causes transient damage 
to cell membranes in highly vascu-
larized organs enabling siRNAs to 
access the cytoplasm (McCaffrey et 
al., 2002; Song et al., 2003b). This 
method of injection is dangerous and 
not feasible for human use. However, 
by catheterizing the vein draining an 
organ, it is possible to raise vascular 
pressure locally to introduce siRNAs 
that are therapeutically beneficial 
(Hamar et al., 2004). These early 
studies suggested that naked siR-
NAs would not be internalized after 
conventional intravenous injection 
into most tissues. However, a sensi-
tive detailed tissue survey has never 
been reported, raising the possibility 
that some cell types or tissues might 
actually be amenable to systemic 
targeting.
To target most tissues deep within 
the body, clinically feasible noninva-
sive strategies need to be devised 
for directing siRNAs into cells. In 
the past year, several approaches 
have achieved impressive thera-
peutic benefit following intravenous 
injection into mice and primates 
using reasonable doses of siRNAs 
without apparent limiting toxicities 
(Figure 2). One approach involves 
covalently coupling the passenger 
strand of the siRNA to cholesterol to 
facilitate uptake through ubiquitously 
expressed cell-surface LDL recep-
tors (Soutschek et al., 2004). This 
approach targeted siRNAs to the 
liver and jejunum. In fact, because 
of its rich vascular supply and role 
as the blood filtering and detoxifying 
organ, the liver is the internal organ 
that is probably easiest to target. 
Silencing the cholesterol transport 
protein ApoB with cholesterol-con-
jugated chemically stabilized ApoB 
siRNAs reduced serum cholesterol 
in mice by about 30%. However, 
this therapeutic effect required a 
high siRNA dose (?50 mg/kg) that is 
unlikely to be applicable to humans. 
A similarly impressive decrease in 
serum cholesterol could be achieved 
by designing a cholesterol-con-
jugated stabilized siRNA, with an 
active strand that is complementary 
to an endogenous microRNA (miR-
122) expressed primarily in the liver. 
Such an siRNA is designed to inter-
fere with the ability of the microRNA 
to silence its targets (Krutzfeldt et al., 
2005). Drugs based on siRNAs that 
mimic or antagonize endogenous 
microRNA function may be of value 
in treating cancer because micro-
RNAs are important for regulating 
cellular differentiation, which goes 
awry during tumor formation (Croce 
and Calin, 2005; Hammond, 2006). 
Conjugating siRNAs to other small 
molecules, either natural ligands for 
cell-surface receptors or small mol-
ecule drugs, would theoretically pro-
vide alternate ways to target specific 
subsets of cells bearing the specified receptor. Although all cells bear cho-
lesterol receptors, steering siRNAs 
into specific cell types by chemically 
conjugating them to ligands for cell-
type-specific receptors would be 
likely to reduce the necessary drug 
dose as well as limit toxicity to unin-
tended bystander cells.
Another strategy for delivering siR-
NAs to the liver involves encapsulat-
ing siRNAs into specialized liposomes 
formed using polyethylene glycol to 
reduce uptake by scavenger cells 
and enhance time spent in the circu-
lation. These specialized nucleic acid 
particles (stable nucleic acid-lipid 
particles or SNALPs) delivered siR-
NAs effectively to the liver (and not to 
other organs), reducing the replica-
tion of hepatitis B replicons in mice 
(Morrissey et al., 2005) and ApoB 
expression in nonhuman primates 
(Zimmermann et al., 2006). Delivery 
by SNALPs, a strategy developed by 
Protiva, reduced the effective siRNA 
dose to ≤3 mg/kg/day, a practical 
therapeutic dose. Liposomes, or 
other lipoplex or nanoparticle siRNA 
formulations, can at least in principle 
be varied with respect to size, lipid 
composition, and incorporation of 
targeting molecules to direct siRNAs 
to other treatment sites.
A cell-specific targeting strategy, 
effective at ?1 mg/kg siRNA dose 
in a mouse tumor model, involves 
mixing siRNAs with a fusion pro-
tein composed of a targeting anti-
body fragment linked to protamine, 
the basic protein that nucleates 
DNA in sperm and binds siRNAs by 
charge (Song et al., 2005). These 
fusion proteins can deliver siRNAs 
with exquisite specificity to a wide 
variety of cells, including primary 
hematopoietic cells that are ordinar-
ily difficult to transfect even in vitro. 
Such fusion proteins have delivered 
siRNAs to HIV-infected lymphocytes 
but not uninfected cells (Song et 
al., 2005) and to activated leuko-
cytes but not resting leukocytes (D. 
Peer, P. Zhu, M. Shimaoka, and J.L., 
unpublished data). Because the 
siRNA is not covalently bound, the 
same delivery agent can be used to 
deliver different siRNAs or cocktails 
of siRNAs.Cell 126These examples of systemic siRNA 
delivery are only the beginning but 
suggest that the delivery hurdle is 
not insurmountable. Which approach 
works best will likely depend on the 
target cell and indication.
Pharmacokinetics
Unmodified and uncomplexed siR-
NAs have a very short half-life in the 
blood (~minutes) that limits their use-
fulness as drugs. They are rapidly 
eliminated by renal excretion, which 
is the rate-limiting factor, and also 
degraded somewhat more slowly (T1/2 
?1 hr) by serum RNases. Information 
about the half-life of unmodified siR-
NAs in other bodily fluids, such as 
those bathing the mucosal portals 
of entry and the eye, is not available. 
Given their rapid elimination, the dra-
matic therapeutic effects of unmodi-
fied siRNAs in some animal disease 
models (Bitko et al., 2005; Palliser 
et al., 2006; Song et al., 2003b) are 
indeed impressive and bode well for 
the effectiveness of modified siRNA 
drugs with improved pharmacoki-
netic properties. Once inside a cell, 
the active strand of the siRNA incor-
porated into the RISC appears to be 
incredibly stable as silencing in some 
tissues persists for weeks (Palliser et 
al., 2006; Song et al., 2003b; Zimmer-
mann et al., 2006). Two factors seem 
to control the persistence of silenc-
ing—the rate of cell division of the tar-
geted cell, where siRNA dilution with 
each cell division reduces the siRNA 
concentration, and the presence 
of the target mRNA within the cell. 
Silencing is sustained in slowly divid-
ing cells expressing the target mRNA 
(Song et al., 2003a). Infrequent dos-
ing may be possible for some non-
dividing or slowly dividing tissues, 
such as the brain and the liver, but 
not for other targets, such as cancer 
cells. Whether and how the pres-
ence of the target mRNA enhances 
stability of the siRNA requires further 
investigation but needs to be consid-
ered when designing interventions. 
For example, an siRNA-based micro-
bicide used to prevent viral infection 
might last longer if the siRNAs target 
host receptor genes rather than viral 
genes., July 28, 2006 ©2006 Elsevier Inc. 233
The plasma half-life of siRNAs can 
be extended substantially (from min-
utes to days) by the siRNAs forming 
complexes with other molecules or 
becoming incorporated into parti-
cles (to bypass the renal filtration 
cutoff of ?50 kDa) and by chemical 
modification to avoid exonuclease 
and endonuclease digestion. These 
modifications generally come at the 
price of reduced intracellular silenc-
ing efficiency, presumably because 
the RNAi machinery is optimized 
to handle unmodified endogenous 
RNAs and because the unmodi-
fied active strand is stable once 
inside the cell (at least if the target 
is present). Given that nuclease sen-
sitivity is sequence dependent, one 
intelligent strategy is to minimize the 
amount of chemical modification and 
restrict it to the linkages or residues 
that are most susceptible to attack 
(Soutschek et al., 2004).
Off-Target Effects
All drugs, and siRNAs are no excep-
tion, have unintended off-target 
effects. Some genes containing 
sequences with imperfect comple-
mentarity may be unintentionally 
silenced by mRNA cleavage or by 
translational inhibition (Jackson et 
al., 2003). Off-target effects occur 
by siRNAs mimicking microRNA tar-
get recognition and gene silencing 
(Jackson et al., 2006b). An attrac-
tive method for minimizing off-tar-
get effects was recently described: 
chemical modification of the sec-
ond residue in the active strand of 
the siRNA (a key residue in the seed 
region for endogenous microRNA 
activity) may suppress unintended 
off-target effects without interfer-
ing with silencing of the target gene 
(Jackson et al., 2006a). The rules for 
predicting off-target gene regulation 
are still too crude to be completely 
useful, although sequences with a 
high degree of similarity to the target 
by BLAST search need to be avoided. 
Unintended off-target changes 
in mRNA can be surveyed using 
mRNA microarrays, which generally 
show that few off-target mRNAs are 
reduced by more than 2-fold. How-
ever, for some genes changes of 2-234 Cell 126, July 28, 2006 ©2006 Elsevifold or less may be clinically signifi-
cant. It is more difficult to evaluate 
the extent of unintended changes in 
protein expression. As translational 
inhibition is less effective at silencing 
gene expression than mRNA cleav-
age, the hope is that most of these 
off-target effects will be too weak 
to cause clinical problems. Indeed 
there has been an encouraging lack 
of toxicity so far in both animal and 
early clinical studies. It is unlikely 
that microarray analyses will be 
helpful to screen and modify siRNA 
sequences to predict and minimize 
off-target effects before their clinical 
testing. More likely they will provide 
useful tools to guide modifications if 
unexplained toxicity is observed.
In addition to silencing unintended 
targets, siRNAs could potentially 
cause problems by triggering immune 
and inflammatory pathways. These 
may include the interferon response 
and toll-like receptor (TLR) pathways, 
which are designed to recognize 
double-stranded RNAs of invading 
viral pathogens (Sledz et al., 2003). 
Innate immune cells, which sound 
the alarm during viral invasion, need 
to tolerate endogenous microRNAs 
and can distinguish between foreign 
RNAs and host RNAs. The interferon 
pathway is not efficiently triggered 
by double-stranded RNAs less than 
30 nucleotides in length, providing 
an adequate size window for siRNA 
drugs (the active strand of endog-
enous single-stranded RNAs binding 
to RISC is only about 21 nucleotides 
long). Longer siRNAs that need to 
be processed by Dicer but are still 
below the 30 nucleotide cutoff may 
be more effective at silencing than 21 
nucleotide siRNAs, possibly because 
Dicer processing helps to incorpo-
rate siRNAs into the RISC (Kim et 
al., 2005). In a few animal studies 
showing siRNA therapeutic ben-
efit, induction of interferon-respon-
sive genes has not been detected, 
even with sensitive real-time RT-
PCR assays. Activating TLRs turns 
out to be sequence specific, with 
the preferred trigger being GU-rich 
sequences (Judge et al., 2005). Can-
didate siRNAs for clinical use (and 
for some types of research) will need er Inc.to be screened to verify that they do 
not activate inflammatory pathways. 
Because the number of effective siR-
NAs for any gene is generally large, 
excluding siRNAs that bind to TLRs 
is not likely to preclude silencing any 
target gene. In addition to avoiding 
TLR-activating sequences, chemical 
modifications of the siRNAs that do 
not abrogate silencing can be used to 
block TLR activation. Several strate-
gies are available to bypass the unin-
tended immunostimulatory effects 
of siRNA drugs, and this potential 
toxicity is not likely to impede siRNA 
drug development.
Drug Resistance
For some important clinical applica-
tions, notably treating viral infection 
and cancer, siRNA drug resistance 
by selection of escape mutations of 
the target sequence during viral rep-
lication or cancer cell division is likely 
to develop. This may be more of a 
problem for siRNAs than for other 
types of small molecule drugs, as 
synonymous mutations can interfere 
with siRNA recognition while leav-
ing the encoded protein untouched. 
One way around this potential prob-
lem is to design siRNAs that tar-
get sequences that are conserved 
at the nucleotide level (these exist 
even for highly variable viruses like 
HIV). Another strategy is to use both 
strands of an siRNA to target more 
than one gene or sequence, includ-
ing drug-resistant variants. Alterna-
tively, siRNA cocktails can be used 
to hit multiple genes and, in the case 
of viruses, to target both viral genes 
and host genes. By focusing on tar-
gets that are essential for viral replica-
tion or cell division, resistance muta-
tions are more likely to interfere with 
the underlying fitness of the virus or 
cell. Whether drug resistance devel-
ops more readily for siRNAs than for 
other types of drugs is hard to pre-
dict without doing clinical studies. If 
resistance does prove to be a clinical 
problem, one important advantage 
of siRNA drugs is the relative ease, 
compared to other small molecule 
drugs, with which resistance can be 
overcome by simple changes in the 
siRNA sequence. The same strate-
gies for preventing anticipated drug 
resistance will also lead to the devel-
opment of drugs suitable for treating 
the diversity of viral strains or cancer 
variants.
Interfering with Endogenous 
microRNAs
A potential cause of toxicity of siRNA 
drugs is that introducing exogenous 
siRNAs into a cell can interfere 
with the processing and function of 
endogenous microRNAs. Copiously 
expressing microRNA-like shRNAs, 
either using a virus (Lu and Cullen, 
2004) or gene therapy vector (Grimm 
et al., 2006), interferes with endog-
enous microRNA nuclear export by 
exportin 5. Although siRNA drugs, 
introduced directly into the cyto-
plasm, will not compete with micro-
RNAs at this stage, large intracellular 
siRNA concentrations might com-
pete for limiting amounts of Dicer 
(for longer siRNA precursor drugs) 
or RISC. This consideration might 
set a limit on the number of different 
siRNAs that could be incorporated 
into a drug cocktail. The catalytic 
nature of mRNA cleavage by siRNAs, 
where the same RISC can be recy-
cled over and over to cleave many 
mRNAs, works to the advantage of 
siRNA drugs. In fact, it may take only 
about 1000 siRNA molecules/cell to 
silence gene expression efficiently (a 
rough estimate derived from the fre-
quencies of individual endogenous 
microRNAs in cells). Quantitative 
information about the relative num-
bers of Dicer and RISC molecules 
and endogenous microRNAs in dif-
ferent cells, together with informa-
tion about the numbers of siRNAs 
required for efficient gene silenc-
ing, would be helpful for anticipat-
ing whether this toxicity might be an 
issue. There is a slim hint from the Sirna Therapeutics phase I study of 
intraocular injection of siRNAs tar-
geting the VEGF pathway to treat 
age-related macular degeneration. 
The study results suggested that too 
high a concentration of siRNAs might 
be less effective than lower concen-
trations, but the number of subjects 
treated at each dose is too small to 
draw any conclusions.
Although many of the potential hur-
dles that stand in the way of harness-
ing RNAi for therapy seem surmount-
able, cautious optimism is in order. 
Although the anticipated problems 
seem to be solvable, it is often the 
unanticipated problems that side-
track drug development.
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